Rede D'Or São Luiz (RDOR3) Q2 2025 earnings summary

Executive summary

• Revenue grew 11.5% year-over-year in Q2 2025, reaching BRL 15.1 billion, with net income surpassing BRL 1.1 billion, up 12.9% year-over-year, and strong operational and financial performance across hospital and insurance segments.

• Operational beds increased by 556 in the semester, totaling over 10,400, supporting organic and inorganic expansion, including partnerships and new hospital projects.

• SulAmérica integration contributed to consolidated results, with net revenue up 10.7% year-over-year to BRL 8.1 billion and a 9.3% increase in health and dental beneficiaries.

• Strong cash generation and improved working capital, with operational cash flow for 6M25 at BRL 4.6 billion, up 22.4% year-over-year.

• Artificial intelligence and digital initiatives are underway to drive administrative and operational efficiency, especially in fraud detection and productivity.

Financial highlights

• Consolidated EBITDA for Q2 2025 was BRL 2.5 billion, up 18.4% year-over-year, with a margin of 25.9%; adjusted EBITDA for SulAmérica was BRL 730 million, up 50% year-over-year.

• Gross revenue for hospital services in Q2 2025 was BRL 9.0 billion, up 13.8% year-over-year; oncology segment gross revenue reached BRL 940 million, up 17.7% year-over-year.

• Adjusted net income for Q2 2025 was BRL 1.2 billion, and for six months, BRL 2.148 billion.

• Operational cash flow grew 22.4% year-over-year to BRL 4.6 billion in the quarter.

• Administrative expenses for SulAmérica at 4.7% of revenue; hospital G&A expenses at 3.6% of gross revenue.

Outlook and guidance

• Over 30 organic expansion projects underway, targeting 3,000 new beds by 2028, with ongoing investments in hospital expansion and digital transformation.

• Management expects continued growth in patient volume, bed capacity, and insurance beneficiaries, with ongoing integration of SulAmérica.

• Ongoing ramp-up of nine hospitals is expected to contribute over two points to gross margin within 24 months.

• IFRS 17 adoption for insurance contracts impacts SulAmérica's reported results, but managerial analysis maintains comparability using previous standards.